Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: An in vitro study

Michael Laposata, Stephen M. Johnson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: If a low-molecular-weight heparin (LMWH) injectable formulation maintains its stability for up to 30 days, substantial cost reductions in hospital stay could be achieved with its use on an outpatient basis in patients who might otherwise be treated with IV heparin as inpatients. Objective: This study was designed to assess the stability for up to 30 days of injectable solutions of the LMWH dalteparin sodium when repackaged in plastic syringes. Methods: In the first part of the study, 1-mL and 3-mL plastic syringes were filled with the contents of a 10,000-IU/mL dalteparin ampule or a 25,000-IU/mL dalteparin multidose vial. In a separate part of the study, 1-mL and 3-mL syringes were filled with doses of 7500 IU and 10,000 IU, respectively, from a 10,000-IU/mL multidose vial. After the syringes were brought to room temperature or 4°C, the stability of dalteparin was assessed over 30 days by measuring anti-factor Xa levels. Results: No significant loss of dalteparin activity was found for up to 30 days in the syringes after storage at room temperature or 4°C. The solutions retained anti-factor Xa activity at room temperature and under refrigeration. Conclusion: Dalteparin is stable for up to 30 days when stored at room temperature or 4°C. The findings suggest that preparation of a postdischarge supply of dalteparin is feasible, contributing to more convenient and effective management of outpatients at risk for thrombotic complications.

Original languageEnglish (US)
Pages (from-to)1219-1225
Number of pages7
JournalClinical Therapeutics
Volume25
Issue number4
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Dalteparin
Syringes
Factor Xa
Temperature
Low Molecular Weight Heparin
Plastics
Outpatients
Refrigeration
Injections
In Vitro Techniques
Heparin
Inpatients
Length of Stay
Costs and Cost Analysis

Keywords

  • Anti-factor Xa
  • Anticoagulants
  • Dalteparin
  • Deep-vein thrombosis
  • Low-molecular-weight heparin
  • Stability
  • Storage
  • Syringes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days : An in vitro study. / Laposata, Michael; Johnson, Stephen M.

In: Clinical Therapeutics, Vol. 25, No. 4, 01.04.2003, p. 1219-1225.

Research output: Contribution to journalArticle

@article{b9b0f85bce4a42bb947d62ebab49d470,
title = "Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: An in vitro study",
abstract = "Background: If a low-molecular-weight heparin (LMWH) injectable formulation maintains its stability for up to 30 days, substantial cost reductions in hospital stay could be achieved with its use on an outpatient basis in patients who might otherwise be treated with IV heparin as inpatients. Objective: This study was designed to assess the stability for up to 30 days of injectable solutions of the LMWH dalteparin sodium when repackaged in plastic syringes. Methods: In the first part of the study, 1-mL and 3-mL plastic syringes were filled with the contents of a 10,000-IU/mL dalteparin ampule or a 25,000-IU/mL dalteparin multidose vial. In a separate part of the study, 1-mL and 3-mL syringes were filled with doses of 7500 IU and 10,000 IU, respectively, from a 10,000-IU/mL multidose vial. After the syringes were brought to room temperature or 4°C, the stability of dalteparin was assessed over 30 days by measuring anti-factor Xa levels. Results: No significant loss of dalteparin activity was found for up to 30 days in the syringes after storage at room temperature or 4°C. The solutions retained anti-factor Xa activity at room temperature and under refrigeration. Conclusion: Dalteparin is stable for up to 30 days when stored at room temperature or 4°C. The findings suggest that preparation of a postdischarge supply of dalteparin is feasible, contributing to more convenient and effective management of outpatients at risk for thrombotic complications.",
keywords = "Anti-factor Xa, Anticoagulants, Dalteparin, Deep-vein thrombosis, Low-molecular-weight heparin, Stability, Storage, Syringes",
author = "Michael Laposata and Johnson, {Stephen M.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0149-2918(03)80078-4",
language = "English (US)",
volume = "25",
pages = "1219--1225",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days

T2 - An in vitro study

AU - Laposata, Michael

AU - Johnson, Stephen M.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Background: If a low-molecular-weight heparin (LMWH) injectable formulation maintains its stability for up to 30 days, substantial cost reductions in hospital stay could be achieved with its use on an outpatient basis in patients who might otherwise be treated with IV heparin as inpatients. Objective: This study was designed to assess the stability for up to 30 days of injectable solutions of the LMWH dalteparin sodium when repackaged in plastic syringes. Methods: In the first part of the study, 1-mL and 3-mL plastic syringes were filled with the contents of a 10,000-IU/mL dalteparin ampule or a 25,000-IU/mL dalteparin multidose vial. In a separate part of the study, 1-mL and 3-mL syringes were filled with doses of 7500 IU and 10,000 IU, respectively, from a 10,000-IU/mL multidose vial. After the syringes were brought to room temperature or 4°C, the stability of dalteparin was assessed over 30 days by measuring anti-factor Xa levels. Results: No significant loss of dalteparin activity was found for up to 30 days in the syringes after storage at room temperature or 4°C. The solutions retained anti-factor Xa activity at room temperature and under refrigeration. Conclusion: Dalteparin is stable for up to 30 days when stored at room temperature or 4°C. The findings suggest that preparation of a postdischarge supply of dalteparin is feasible, contributing to more convenient and effective management of outpatients at risk for thrombotic complications.

AB - Background: If a low-molecular-weight heparin (LMWH) injectable formulation maintains its stability for up to 30 days, substantial cost reductions in hospital stay could be achieved with its use on an outpatient basis in patients who might otherwise be treated with IV heparin as inpatients. Objective: This study was designed to assess the stability for up to 30 days of injectable solutions of the LMWH dalteparin sodium when repackaged in plastic syringes. Methods: In the first part of the study, 1-mL and 3-mL plastic syringes were filled with the contents of a 10,000-IU/mL dalteparin ampule or a 25,000-IU/mL dalteparin multidose vial. In a separate part of the study, 1-mL and 3-mL syringes were filled with doses of 7500 IU and 10,000 IU, respectively, from a 10,000-IU/mL multidose vial. After the syringes were brought to room temperature or 4°C, the stability of dalteparin was assessed over 30 days by measuring anti-factor Xa levels. Results: No significant loss of dalteparin activity was found for up to 30 days in the syringes after storage at room temperature or 4°C. The solutions retained anti-factor Xa activity at room temperature and under refrigeration. Conclusion: Dalteparin is stable for up to 30 days when stored at room temperature or 4°C. The findings suggest that preparation of a postdischarge supply of dalteparin is feasible, contributing to more convenient and effective management of outpatients at risk for thrombotic complications.

KW - Anti-factor Xa

KW - Anticoagulants

KW - Dalteparin

KW - Deep-vein thrombosis

KW - Low-molecular-weight heparin

KW - Stability

KW - Storage

KW - Syringes

UR - http://www.scopus.com/inward/record.url?scp=0038070280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038070280&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(03)80078-4

DO - 10.1016/S0149-2918(03)80078-4

M3 - Article

C2 - 12809968

AN - SCOPUS:0038070280

VL - 25

SP - 1219

EP - 1225

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -